MetaCap

enGene Therapeutics (ENGN) vs Fate Therapeutics (FATE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed enGene Therapeutics (ENGN) over the past year, losing 10.8% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $111.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%FATE-10.78%
+216%+61%-93%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%FATE-97.64%
+203%+45%-112%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus FATE key metrics
MetricENGNFATE
Share price$1.74$0.919
Market cap$116.61M$111.82M
1-day change-1.14%-9.01%
YTD return-80.73%-6.22%
1-year return-75.00%-10.78%
5-year return—-98.25%
EPS (TTM)$-2.07$-1.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.65M
Revenue growth (YoY)—-51.24%
Net income (latest FY)$-117.30M$-136.31M
Operating margin—-2222.45%
Net margin—-2051.08%
52-week high$12.25$3.23
52-week low$1.40$0.90
Distance from 52-week high-85.80%-71.55%
Analyst consensusbuybuy
Avg. price target upside+146.55%+522.42%
Average volume1.12M1.53M
Shares outstanding67.02M121.67M
Employees81161
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed ENGN by 64.2 percentage points over the past year.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

ENGN vs FATE FAQ

Which is bigger, enGene Therapeutics or Fate Therapeutics?

enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $111.82M for Fate Therapeutics (FATE).

Which stock has performed better over the past year, ENGN or FATE?

FATE returned -10.78% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Fate Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons